https://orcid.org/0000-0003-2795-6507
References
- Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705.
- Molica S, Seymour JF, Polliack A. A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematol Oncol. 2021;39(5):595–604.
- Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019;6(7):e366–e374.
- Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four‐factor prognostic model. J Clin Oncol. 2021;39(6):576–585.
- Gentile M, Morabito F, Del Poeta G, et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2021;35(1):235–238.
- Morabito F, Tripepi G, Del Poeta G, et al. Assessment of the 4‐factor score: retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Am J Hematol. 2021;96(5):E168–E171.
- Molica S, Giannarelli D, Visentin A, et al. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model. Am J Hematol. 2022;97(5):E176–E180.
- Ysebaert L, Michallet AS, Bijou F, et al. Real-world ibrutinib validation of the ball score to predict overall survival: a filo group study in RR CLL patients. Blood. 2019;134(Supplement_1):1741–1741.
- Gentile M, Martino EA, Visentin A, et al. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. Blood Cancer J. 2020;10(9):92.
- Molica S, Baumann TS, Lentini M, et al. The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. Leuk Res. 2020;95:106401.
- Molica S, Baumann T, Giannarelli D. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: results of a comparative performance analysis. Eur J Haematol. 2021;106(3):425–427.
- Moher D, Shamseer L, Clarke M, PRISMA-P Group, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
- Kreuzberger N, Damen JA, Trivella M, et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020;7:CD012022.
- Kater AP, Levin MD, Dubois J, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23(6):818–828.
- Ahn IE, Ruppert AS, Wiestner A, et al. Performance of standard prognostic models in older adults receiving ibrutinib for treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a post hoc analysis of alliance A041202 phase 3 trial. Blood. 2021;138(Supplement 1):2642–2642.